TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Recruiting · NCT06481735 · Registry updated 2026-05-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-05-08 | NCT06481735 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chinese PLA General Hospital | 238 |
| Peking University | 124 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Biotherapeutic Department of Chinese PLA General Hospital | Beijing | China | 8 |
| Department of Hematology, Chinese PLA General Hospital | Beijing | China | 1 |
| Department of Hematology, Heping Hospital Affiliated to Changzhi Medical College | Changzhi | China | 1 |
| Department of Hematology, Peking Union Medical College Hospital | Beijing | China | 1 |
| Department of Hematology, Tianjin First Central Hospital | Tianjin | China | 1 |
| Immune Cell Therapy Center, Blood Disease Hospital, Chinese Academy of Medical Sciences | Tianjin | China | 1 |